For example, in renal cancer organoid models, epigenetic silencing of KAT2B through promoter hypermethylation was shown to drive metabolic reprogramming and tumor progression; restoration of KAT2B or inhibition of its downstream target of FASN-suppressed organoid growth [107]. The gene discussed is KAT2B; the disease is neoplasm.